search
Back to results

Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life (MHE)

Primary Purpose

Chronic Liver Disease, Hepatic Encephalopathy

Status
Completed
Phase
Phase 2
Locations
India
Study Type
Interventional
Intervention
VSL#3
Lactulose
Sponsored by
CD Pharma India Pvt. Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Liver Disease

Eligibility Criteria

15 Years - 80 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All the patients with Chronic Liver Disease or Minimal Hepatic Encephalopathy (without overt hepatic encephalopathy) aged between 15 to 80 years of both the genders would be enrolled consecutively.

Exclusion Criteria:

  • Patients with overt hepatic encephalopathy
  • Active medical co-morbidities like CHD, chronic respiratory disease, chronic renal disease, malignancies, diabetes etc
  • Malignancy
  • History of taking lactulose or probiotics or antibiotics, in the past 6 weeks
  • Presence of other neurological or psychiatric disorder
  • Patients who underwent shunt surgery for portal hypertension
  • History of taking medicines likely to interfere with psychometric performance
  • History of GI hemorrhage or spontaneous bacterial peritonitis during the past 6 weeks
  • Presence of mature cataracts and diabetic retinopathy
  • Refused to participate in the study

Sites / Locations

  • Dept. of Gastroenterology and H.N.U., All India Institute of Medical Sciences

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

VSL#3

Lactulose

Arm Description

30-60 ml of lactulose per day (2 months) to ensure 2-3 soft stools

Outcomes

Primary Outcome Measures

To compare the effect of probiotics and lactulose based on normalization of the abnormal test parameters, Neuropsychometric tests, P3ERP, EEG, venous ammonia levels, Development of overt encephalopathy and other complications and HRQOL

Secondary Outcome Measures

Full Information

First Posted
November 4, 2009
Last Updated
June 3, 2013
Sponsor
CD Pharma India Pvt. Ltd.
Collaborators
Indian Council of Medical Research, All India Institute of Medical Sciences, New Delhi
search

1. Study Identification

Unique Protocol Identification Number
NCT01008293
Brief Title
Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life
Acronym
MHE
Official Title
Health Related Quality of Life in Patient With Chronic Liver Disease and Effect of Probiotics in the Treatment of MHE and Health Related Quality of Life
Study Type
Interventional

2. Study Status

Record Verification Date
June 2013
Overall Recruitment Status
Completed
Study Start Date
October 2009 (undefined)
Primary Completion Date
June 2012 (Actual)
Study Completion Date
October 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
CD Pharma India Pvt. Ltd.
Collaborators
Indian Council of Medical Research, All India Institute of Medical Sciences, New Delhi

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is a randomized, open, parallel group, active comparator, single center trial. Objectives of the study are hereby given below: To study the health related quality of life (HRQOL) in patients with chronic liver disease. To assess the prevalence of minimal hepatic encephalopathy (MHE) in patients with chronic liver disease and assessment of HRQOL in patients with MHE. To compare the effect of probiotics and lactulose in the treatment of MHE To assess the effect of probiotics and lactulose on the HRQOL in patients with MHE.
Detailed Description
The study design would comprise of two parts Part I: Cross sectional study: This part would comprise of the assessment of HRQOL in patients with CLD All the consecutive patients diagnosed as CLD would be enrolled in the study. All these patients would be enrolled from the liver clinics of the department of gastroenterology and those admitted in the gastroenterology ward at AIIMS. Alcohol would be considered to be the cause of CLD, if the patient regularly consumed ≥80g/d of alcohol for five years The staging of cirrhosis would be done according to the Child Pugh classification: A, B and C The causes of CLD would be divided into:- viral hepatitis, alcohol, viral hepatitis combining with alcohol and miscellaneous causes Part II: Prospective randomized controlled trial: In this part the outcome of lactulose and probiotic therapy in the treatment of MHE and its effect on the HRQOL will be compared. All the consecutive patients with CLD without overt encephalopathy would be screened for MHE. All these patients would be enrolled from the liver clinics and the gastroenterology ward, AIIMS. The diagnosis of MHE would be based on abnormal psychometric tests (NCT-A and NCT-B or FCT-A and FCT-B) and /or abnormal P300 auditory event related potentials.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Liver Disease, Hepatic Encephalopathy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
120 (Actual)

8. Arms, Groups, and Interventions

Arm Title
VSL#3
Arm Type
Experimental
Arm Title
Lactulose
Arm Type
Active Comparator
Arm Description
30-60 ml of lactulose per day (2 months) to ensure 2-3 soft stools
Intervention Type
Drug
Intervention Name(s)
VSL#3
Intervention Description
VSL#3 (2 capsules bid.for 2 months, Each containing 112.5 billion viable lyophilized bacteria). Each capsule contains 4 strains of Lactobacillus (L. casei, L. plantarum, L. acidophilus, and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacterium (B. longum, L. breve, and B. infantis), and 1 strain of Streptococcus salivarius subsp. thermophilus (designated hereafter as S. thermophilus)
Intervention Type
Drug
Intervention Name(s)
Lactulose
Other Intervention Name(s)
Duphalac
Intervention Description
30-60 ml of lactulose per day for 2 months to ensure 2-3 soft stools.
Primary Outcome Measure Information:
Title
To compare the effect of probiotics and lactulose based on normalization of the abnormal test parameters, Neuropsychometric tests, P3ERP, EEG, venous ammonia levels, Development of overt encephalopathy and other complications and HRQOL
Time Frame
2 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
15 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All the patients with Chronic Liver Disease or Minimal Hepatic Encephalopathy (without overt hepatic encephalopathy) aged between 15 to 80 years of both the genders would be enrolled consecutively. Exclusion Criteria: Patients with overt hepatic encephalopathy Active medical co-morbidities like CHD, chronic respiratory disease, chronic renal disease, malignancies, diabetes etc Malignancy History of taking lactulose or probiotics or antibiotics, in the past 6 weeks Presence of other neurological or psychiatric disorder Patients who underwent shunt surgery for portal hypertension History of taking medicines likely to interfere with psychometric performance History of GI hemorrhage or spontaneous bacterial peritonitis during the past 6 weeks Presence of mature cataracts and diabetic retinopathy Refused to participate in the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Y K Joshi, Prof.
Organizational Affiliation
All India Institute of Medical Sciences, New Delhi
Official's Role
Principal Investigator
Facility Information:
Facility Name
Dept. of Gastroenterology and H.N.U., All India Institute of Medical Sciences
City
New Delhi
State/Province
Delhi
ZIP/Postal Code
110029
Country
India

12. IPD Sharing Statement

Learn more about this trial

Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life

We'll reach out to this number within 24 hrs